That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...

Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...

AstraZeneca also got approval to sell Breztri Aerosphere, a COPD treatment, and plans to launch it in January 2025. AstraZeneca Pharma India focuses on oncology, cardiovascular diseases ...

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the cancer treatment drug Olaparib, branded as Lynparza, in ...

At the same time, AstraZeneca also launched its latest triple therapy, Breztri Aerosphere® to cater to the unmet needs of patients living with chronic obstructive pulmonary disease (COPD).

UBS analyst Matthew Weston upgraded AstraZeneca (AZN – Research Report) to a Hold today and set a price target of £113.00. The company’s shares closed yesterday at p10,030.00. Don't Miss out ...

Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday’s intraday deals. This came after the company announced that it will launch Breztri Aerosphere in ...

AstraZeneca Pharma: The pharmaceutical company will launch Breztri Aerosphere in January 2025 in India. Breztri Aerosphere is used to relieve symptoms and prevent exacerbations in adult patients ...

AstraZeneca Pharma India rose 1.84% to Rs 6,515.50 after the durg maker said that it will launch Breztri Aerosphere in January 2025 in India. Earlier, on 2 December 2023, the pharma company intimated ...

A collection of the most-viewed Moneycontrol videos. Fall of Assad: Israeli Troops, Tanks Deployed in Buffer Zone with Syria Advisory Alert: It has come to our attention that certain individuals ...

Elsewhere, AstraZeneca last month shelled out $100 million for CSPC Pharmaceutical Group’s preclinical heart disease candidate YS2302018. Like Lilly’s muvalaplin, the prospect AZ has acquired ...